What the cohort followed
A single-center retrospective study followed 85 adults with drug-resistant focal epilepsy who still had seizures while taking cenobamate and subsequently received low-dose clobazam. Researchers tracked seizure outcomes, adverse reactions and whether participants remained on treatment.
The percentages describe different events
The investigators reported an estimated 12-month treatment retention rate of 83.1%. They separately defined a seizure responder as someone with at least a 50% reduction in seizure frequency. Staying on medication can reflect tolerability and practical decisions as well as symptom control. The adverse-reaction records identified somnolence as the most frequent reaction.
Check who contributed outcome data
When citing a later seizure endpoint, identify which patients had reached the follow-up and had measurements available. Then examine the treatment-retention method and reasons for stopping. The study had no concurrent cenobamate-only control group, which limits attempts to attribute the observed changes to the addition of clobazam alone.
Leave a Reply